Significantly lower risk is seen for progression, cases, and viral clearance. 3 studies from 3 independent teams in 3 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 79% [66‑87%] lower risk. Currently all studies are RCTs.
Currently there is limited data, with only 509 patients in trials to date. Studies to date are from only 3 different groups.
4 RCTs with 512 patients have not reported results (up to 3 years late).
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Chlorhexidine may be detrimental to the natural microbiome, raising concern for side effects, especially with prolonged or excessive use. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Dec 2024, preprint, 1 author.
